Identification and characterization of cancer stem cells in gastrointestinal stromal tumors for overcome Glivec-resistance

Research Project

Project/Area Number	20591579
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Single-year Grants
Section	一般
Research Field	Digestive surgery
Research Institution	Keio University
Principal Investigator	SAIKAWA Yoshiro Keio University, 医学部, 講師 (00225682)
Project Period (FY)	2008 – 2010
Project Status	Completed (Fiscal Year 2010)
Budget Amount *help	¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000) Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000) Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000) Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords	GIST / 癌幹細胞 / CD133 / グリベック / がん幹細胞
Research Abstract	Some evidences have suggested that CD133/Prominin1 is a marker for a subset of cancer stem like cells in solid tumors. Our study for the first time provided evidence that CD133 positive cancer stem cells display capability on tumorigenesis and resistance to glivec. CD133 is expressed in the minority of GISTs, suggesting a novel, additional standard marker for identifying cancer stem cells (CSCs). Future studies should focus on the role of CD133 in the pathogenesis of GIST and subsequently on its potential to act as a molecular target for adjuvant therapy with new molecular antitumor agents.